PubMed:32471876 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":29,"end":37},"obj":"SP_7"},{"id":"T2","span":{"begin":146,"end":149},"obj":"GO:0016265"},{"id":"T3","span":{"begin":155,"end":163},"obj":"SP_7"},{"id":"T4","span":{"begin":169,"end":175},"obj":"NCBITaxon:9606"},{"id":"T5","span":{"begin":319,"end":337},"obj":"CHEBI:5801"},{"id":"T6","span":{"begin":319,"end":337},"obj":"DG_20"},{"id":"T7","span":{"begin":319,"end":337},"obj":"CHEBI:5801"},{"id":"T8","span":{"begin":343,"end":355},"obj":"CHEBI:2955"},{"id":"T9","span":{"begin":343,"end":355},"obj":"DG_6"},{"id":"T10","span":{"begin":343,"end":355},"obj":"CHEBI:2955"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Registries Offer Insights on COVID-19-Cancer Connection.\nFindings from CCC19 and TERAVOLT suggest that patients with cancer may be more likely to die from COVID-19 than people in the general population. Additional mortality risk factors may include age, performance status, treatment with chemotherapy, and exposure to hydroxychloroquine plus azithromycin."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":38,"end":44},"obj":"Phenotype"},{"id":"T2","span":{"begin":117,"end":123},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Registries Offer Insights on COVID-19-Cancer Connection.\nFindings from CCC19 and TERAVOLT suggest that patients with cancer may be more likely to die from COVID-19 than people in the general population. Additional mortality risk factors may include age, performance status, treatment with chemotherapy, and exposure to hydroxychloroquine plus azithromycin."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":29,"end":37},"obj":"Disease"},{"id":"T2","span":{"begin":38,"end":44},"obj":"Disease"},{"id":"T3","span":{"begin":117,"end":123},"obj":"Disease"},{"id":"T4","span":{"begin":155,"end":163},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Registries Offer Insights on COVID-19-Cancer Connection.\nFindings from CCC19 and TERAVOLT suggest that patients with cancer may be more likely to die from COVID-19 than people in the general population. Additional mortality risk factors may include age, performance status, treatment with chemotherapy, and exposure to hydroxychloroquine plus azithromycin."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":319,"end":337},"obj":"Chemical"},{"id":"T2","span":{"begin":343,"end":355},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_2955"}],"text":"Registries Offer Insights on COVID-19-Cancer Connection.\nFindings from CCC19 and TERAVOLT suggest that patients with cancer may be more likely to die from COVID-19 than people in the general population. Additional mortality risk factors may include age, performance status, treatment with chemotherapy, and exposure to hydroxychloroquine plus azithromycin."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1","span":{"begin":29,"end":44},"obj":"Disease"},{"id":"10","span":{"begin":81,"end":89},"obj":"Chemical"},{"id":"11","span":{"begin":103,"end":111},"obj":"Species"},{"id":"12","span":{"begin":117,"end":123},"obj":"Disease"},{"id":"13","span":{"begin":155,"end":163},"obj":"Disease"},{"id":"14","span":{"begin":169,"end":175},"obj":"Species"},{"id":"15","span":{"begin":214,"end":223},"obj":"Disease"},{"id":"16","span":{"begin":319,"end":337},"obj":"Chemical"},{"id":"17","span":{"begin":343,"end":355},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"tao:has_database_id","subj":"1","obj":"MESH:C000657245"},{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"Tax:9606"},{"id":"A12","pred":"tao:has_database_id","subj":"12","obj":"MESH:D009369"},{"id":"A13","pred":"tao:has_database_id","subj":"13","obj":"MESH:C000657245"},{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"Tax:9606"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:D003643"},{"id":"A16","pred":"tao:has_database_id","subj":"16","obj":"MESH:D006886"},{"id":"A17","pred":"tao:has_database_id","subj":"17","obj":"MESH:D017963"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Registries Offer Insights on COVID-19-Cancer Connection.\nFindings from CCC19 and TERAVOLT suggest that patients with cancer may be more likely to die from COVID-19 than people in the general population. Additional mortality risk factors may include age, performance status, treatment with chemotherapy, and exposure to hydroxychloroquine plus azithromycin."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":56},"obj":"Sentence"},{"id":"T2","span":{"begin":57,"end":202},"obj":"Sentence"},{"id":"T3","span":{"begin":203,"end":356},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Registries Offer Insights on COVID-19-Cancer Connection.\nFindings from CCC19 and TERAVOLT suggest that patients with cancer may be more likely to die from COVID-19 than people in the general population. Additional mortality risk factors may include age, performance status, treatment with chemotherapy, and exposure to hydroxychloroquine plus azithromycin."}

{"project":"hydroxychloroquine","denotations":[{"id":"T1","span":{"begin":38,"end":44},"obj":"Phenotype"},{"id":"T2","span":{"begin":117,"end":123},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Registries Offer Insights on COVID-19-Cancer Connection.\nFindings from CCC19 and TERAVOLT suggest that patients with cancer may be more likely to die from COVID-19 than people in the general population. Additional mortality risk factors may include age, performance status, treatment with chemotherapy, and exposure to hydroxychloroquine plus azithromycin."}